MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1480-1491

  Wang, Wei ^a   Wang, Ying Qing ^a   Meng, Tao ^a   Yi, Jun Mei ^a   Huan, Xia Juan ^a   Ma, Lan Ping ^a   Tong, Lin Jiang ^a   Chen, Yi ^a   Ding, Jian ^a   Shen, Jing Kang ^a   Miao, Ze Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MT 189; PROTEIN BCL 2; PROTEIN MCL 1; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; 2-(6-FLUORO-3-((4-METHOXYBENZYL)AMINO)IMIDAZO(1,2-ALPHA)PYRIDIN-2-YL)PHENOL; IMIDAZOLE DERIVATIVE; MAP KINASE KINASE KINASE 7; MAP2K4 PROTEIN, HUMAN; MAP3K1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MYELOID LEUKEMIA FACTOR 1; PYRIDINE DERIVATIVE; TUBULIN; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; DRUG EFFECTS; HT 29 CELL LINE; METABOLISM; NEOPLASMS; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; HT29 CELLS; HUMANS; IMIDAZOLES; MAP KINASE KINASE 4; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASES; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PHOSPHORYLATION; PROTEOLYSIS; PYRIDINES; TUBULIN; TUBULIN MODULATORS;

EID: 84902681680     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0629     Document Type: Article

References (41)

1. Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943-71.
2. Meng T, Zhang Z, Hu D, Lin L, Ding J, Wang X, et al. Three-component combinatorial synthesis of a substituted 6H-pyrido[2́,1́:2,3] imidazo- [4,5-c]isoquinolin-5(6H)-one library with cytotoxic activity. J Comb Chem 2007;9:739-41.
3. Zhang Z, Meng T, He J, Li M, Tong LJ, Xiong B, et al. MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. Invest New Drugs 2010;28:715-28.
4. Zhang Z, Meng T, Yang N, Wang W, Xiong B, Chen Y, et al. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Int J Cancer 2011;129:214-24.
5. Meng T, Wang W, Zhang Z, Ma L, Zhang Y, Miao Z, et al. Synthesis and biological evaluation of 6H-pyrido[2′,1′:2,3]imidazo[4,5-c] isoquinolin-5(6H)-ones as antimitotic agents and inhibitors of tubulin polymerization. Bioorg Med Chem 2014;22:848-55.
6. Eisenloffel C, Schmole AC, Pews-Davtyan A, Brennfuhrer A, Kuznetsov SA, Hubner R, et al. Interference of a novel indolylmaleimide with microtubules induces mitotic arrest and apoptosis in human progenitor and cancer cells. Biochem Pharmacol 2013;85:763-71.
7. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, et al. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005;11:6002-11. (Pubitemid 41170332)
8. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, et al. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. J Mol Med 2012;90:971-81.
9. Li MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP, et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 2004;10:8266-74. (Pubitemid 40053386)
10. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012;143:307-20.
11. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF (FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011;471:104-9.
12. Chu R, Terrano DT, Chambers TC. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem Pharmacol 2012;83:199-206.
13. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003;106:108-15. (Pubitemid 36750396)
14. Yao HD, Wu Q, Zhang ZW, Zhang JL, Li S, Huang JQ, et al. Gene expression of endoplasmic reticulum resident selenoproteins correlates with apoptosis in various muscles of se-deficient chicks. J Nutr 2013;143:613-9.
15. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, et al. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 2006;69:1226-33.
16. Lorenzo C, Liao Q, Hardwicke MA, Ducommun B. Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics. Cell Cycle 2009;8:1733-7.
17. Chen CH, Liao CH, Chang YL, Guh JH, Pan SL, Teng CM. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. Cancer Lett 2012;315:1-11.
18. Zhou J, Yao J, Joshi HC. Attachment and tension in the spindle assembly checkpoint. J Cell Sci 2002;115:3547-55.
19. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004;7:637-51. (Pubitemid 39462685)
20. Hwang JH, Takagi M, Murakami H, Sekido Y, Shin-ya K. Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound JBIR-23. Cancer Lett 2011;300:189-96.
21. Aneja R, Liu M, Yates C, Gao J, Dong X, Zhou B, et al. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res 2008;68:1495-503. (Pubitemid 351346858)
22. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008;27:6194-206.
23. Inoue S, Browne G, Melino G, Cohen GM. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 2009;16:1053-61.
24. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011;21:92-101.
25. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010;17:883-94.
26. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20:1017-27. (Pubitemid 43797292)
27. Kim JA, Lee J, Margolis RL, Fotedar R. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene 2010;29:1702-16.
28. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol 2012;19:140-54.
29. Borowiec AS, Bidaux G, Tacine R, Dubar P, Pigat N, Delcourt P, et al. Are Orai1 and Orai3 channels more important than calcium influx for cell proliferation? Biochim Biophys Acta 2014;1843:464-72.
30. Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 2014;14:32.
31. Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 2013;12:3689-701.
32. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, Chambers TC. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 2000;275:29980-5.
33. Nepali K, Ojha R, Sharma S, Ojha A, Bedi PM, Dhar KL. Tubulin inhibitors: a patent survey. Recent Pat Anticancer Drug Discov. Epub 2013 May 30.
34. Sakurikar N, Eichhorn JM, Chambers TC. Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. J Biol Chem 2012;287:39193-204.
35. Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis 2014;5:e1052.
36. Bates DJ, Danilov AV, Lowrey CH, Eastman A. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Mol Cancer Ther 2013;12:1504-14.
37. Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60. (Pubitemid 28496124)
38. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-36. (Pubitemid 28108645)
39. Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003;63:4527-32. (Pubitemid 36951025)
40. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, et al. c-Jun protects hypoxia-inducible factor-1alpha from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner. Cancer Res 2009;69:7704-12.
41. Miao ZH, Feng JM, Ding J. Newly discovered angiogenesis inhibitors and their mechanisms of action. Acta Pharmacol Sin 2012;33:1103-11.